FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

Coronary Artery Disease Clinical Trial

— SLIM  

Official title:

Ischemia (FFR) Driven Complete Revascularization Versus Usual Care in Patients With Non-ST Elevation Myocardial Infarction and Multivessel Diseases: The South Limburg Myocardial Infarction Study Group The SLIM Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03562572
• Other study ID #: 17-T-142
• Secondary ID: 28708
• Status: Recruiting
• Phase: N/A
• Start date: June 7, 2018
• Est. completion date: January 1, 2028

Study information

• Verified date: February 2023
• Source: Zuyderland Medisch Centrum
• Contact: Tobias Pustjens, Drs.
• Phone: +31884597777
• Email: t.pustjens[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease.

Description:

Background: Patients with non-ST elevation myocardial infarction (non-STEMI), as compared with STEMI patients, have a higher risk profile, more often MVD and less favourable outcome. Recent studies showed that complete revascularization in STEMI patients is feasible and effective. However, there is no clear evidence regarding the role of complete coronary revascularization by PCI in patients with non-STEMI with MVD. Objective: To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease. Design: Prospective, multicentre, 1:1 randomized, investigator initiated study. Hypothesis: FFR guided complete percutaneous revascularisation of all significant stenosis in the non-culprit lesion performed within the index PCI procedure will improve clinical outcomes compared to the usual care, guided by discretion of the physician.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 476
• Est. completion date: January 1, 2028
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients aged between 18-85 years presenting with non-STEMI according to current guidelines, who will be treated with PCI of the culprit and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.
• Non-IRA stenosis amenable for PCI treatment (operator's decision)
• Signed informed consent

Exclusion Criteria:

• Left main disease (stenosis > 50%)
• Chronic total occlusion of a non-IRA
• Indication for or previous coronary artery bypass grafting
• Uncertain culprit lesion
• Complicated IRA treatment, e.g. extravasation, permanent no re-flow after IRA treatment (TIMI flow 0-1) and inability to implant a stent
• Known severe cardiac valve dysfunction that will require surgery or TAVI in the follow-up period.
• Killip class III or IV during the completion of culprit lesion treatment.
• Life expectancy of < 1 year.
• Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor or Heparin.
• Gastrointestinal or genitourinary bleeding within the prior 3 months.
• Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
• Pregnancy

Related Conditions & MeSH terms

• Coronary Artery Disease
• Fractional Flow Reserve, Myocardial
• Myocardial Revascularization
• Non-ST Elevated Myocardial Infarction
• NSTEMI - Non-ST Segment Elevation MI
• Percutaneous Coronary Intervention

Intervention

Procedure:
• Ischemia driven revascularization
In the ischemia driven complete revascularisation strategy group all flow limiting (FFR = 0.80) lesions will receive treatment by PCI and stenting during the index intervention

Other:
• Usual care group
In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.

Locations

Country	Name	City	State
Czechia	Brno University Hospital	Brno
Hungary	Gottsegen György Országos Kardiológiai Intézet	Budapest
Hungary	Bacs-Kiskun Teaching Hospital	Kecskemét
Hungary	Szeged University	Szeged
Netherlands	Jeroen Bosch Ziekenhuis	Den Bosch
Netherlands	Zuyderland MC	Heerlen
Netherlands	Maastricht University Medical Centre	Maastricht
Netherlands	Viecuri Medisch Centrum	Venlo

Sponsors (9)

Lead Sponsor	Collaborator
Zuyderland Medisch Centrum	Bács-Kiskun County Teaching Hospital, Brno University Hospital, Gottsegen György Országos Kardiológiai Intézet, Jeroen Bosch Ziekenhuis, Maastricht University Medical Center, Radboud University Medical Center, Szeged University, VieCuri Medical Centre

Countries where clinical trial is conducted

Czechia,  Hungary,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of MACE at 12 months	MACE = The composite endpoint of all cause death, non-fatal Myocardial Infarction, any revascularisation and stroke at 12 months.	12 months
Secondary	The incidence of MACE in subgroups at 12 and 24 months.	Prespecified subgroup analyses of primary outcomes will be performed for: Diabetic patients versus non-diabetic patients; Elderly (= 75 years) versus young patients (< 75 years); Male versus Female gender; High versus low risk patients according to GRACE Risk Score; Patients previous myocardial infarction versus patients with no previous myocardial infarction; The Global Registry of Acute Coronary Events (GRACE) score estimates the admission 6 month mortality for patients with acute coronary syndrome. The GRACE score ranges from 0 to > 285. A higher GRACE represents a higher mortality risk, ranging from 0-2% when the GRACE is between 0 and 87, to 99% when the GRACE exceeds 285.	12 and 24 months
Secondary	Composite endpoint of Net Adverse Clinical Events (NACE) defined as composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and major bleeding at 12, 24 and 36 months.		12, 24 and 36 months
Secondary	Composite endpoint hospitalisation for heart failure and unstable angina pectoris at 12, 24 and 36 months.		12, 24 and 36 months
Secondary	All-cause mortality or Myocardial infarction at 12, 24 and 36 months.		12, 24 and 36 months
Secondary	Any revascularisation at 12, 24 and 36 months.		12, 24 and 36 months
Secondary	Stent thrombosis at 12, 24 and 36 months.		12, 24 and 36 months
Secondary	Bleeding (major and minor) at 48 hours and 12 months.		48 hours and 12 months
Secondary	The incidence of MACE at 36 months as well as outcomes of each component of MACE at 12 and 24 and 36 months.	MACE = The composite endpoint of all cause death, non-fatal Myocardial Infarction, any revascularisation and stroke at 12 months.	12, 24 and 36 months
Secondary	Left ventricular ejection fraction at 12 and 24 and 36 month (MIBI scan, MRI or Echocardiography).		12, 24 and 36 months